Relevant search


    Corporate Overview

    Winhealth is a China-based, Asia Pacific centric, innovative biotechnology company, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The company is headquartered in Hong Kong, with operating hubs in Hangzhou, Shanghai, and Beijing. The company owns China's first rare disease managed access platform in Bo'ao, Hainan. The company also has representative offices in Japan, Singapore and Europe. Winhealth also has a strategic stake in the Cumberland Emerging Technologies (CET) program in the United States, focuses on development and licensing in novel breakthrough therapies in the medical field, as well as is committed to collaborating with relevant medical schools and research institutes in China.

    The Company enters into target markets primarily through the accelerated introduction of novel breakthrough therapies from international biotechnology companies to serve patients with rare diseases and other unmet medical needs.

    Winhealth has built a unique, balanced and diversified portfolio with numerous innovative rare disease and specialty products at commercial and late clinical stages, some with blockbuster potential. The company is also continuously looking to bring in more innovative therapies from the globe.

    Vision, Mission & Values
    We Leave No One Behind.
    To build a leading rare disease ecosystem in Asia Pacific.
    Providing novel breakthrough therapies for patients with rare diseases and other unmet medical needs.
    Winhealth adheres to the highest standard of the following core values in our daily operations.

    Responsibility: We take utmost responsibility for our stakeholders including patients, physicians, shareholders, partners, and employees.

    Audacious Innovation: We aim to foster creative thinking and take smart risks that leads to practical solutions to challenges.

    Result-Driven: We are committed to delivering superior results for our stakeholders in a sustainable way.

    Entrepreneurship: We constantly take initiatives to foster entrepreneurship.

    Major Investors
    • LYFE Capital
      Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.27 billion in assets under management. LYFE Capital is actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets. LYFE Capital's investments focus spans biopharmaceuticals, medical devices, and diagnostics.
      KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in venture capital, private equity, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of KAITAI CAPITAL has reached 50 billion RMB (USD$7.2B) .
    Selected Partners

    This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information please read here.